BioSpace News Archive

Centene Corporation (NYSE: CNC) announced today its North Carolina subsidiary, WellCare of North Carolina , will help coordinate physical health services for multiple Local Management Entities/Managed Care Organizations (LME/MCOs) for the state’s Behavioral Health and Intellectual/Developmental Disability Tailored Plans

Orthofix Medical Inc., a global medical device company with a spine and orthopedics focus, announced the first patient implant in a U.S. Food and Drug Administration clinical study that will evaluate the safety and effectiveness of the M6-C™ artificial cervical disc compared to anterior cervical discectomy and fusion for the treatment of contiguous two-level symptomatic cervical radiculopathy.

AstraZeneca’s SAPHNELO™ has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus who are receiving standard therapy.

IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, announced that it will hold a conference call and webcast on Wednesday, August 11, 2021 at 8:00 a.m. ET to discuss the company’s second quarter 2021 financial and operational results.

Cyteir Therapeutics, Inc. announced that its President and Chief Executive Officer Markus Renschler, MD will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually on August 10, 2021.

Ipsen and Exicure Inc. have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids as potential investigational treatments for Huntington’s disease and Angelman syndrome.

GC Pharma, a South Korean biopharmaceutical company, announced unaudited consolidated financial results for the three months ended 30 June 2021.

Biophytis SA, is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces the top line results of the SARA-INT phase 2 clinical study with Sarconeos in Sarcopenia:

Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 in China.

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the market opens, followed by a conference call.